ANRS 176 RHIVIERA-02

A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control.

Last updated on 22 May 2024

Primary objective

Evaluate if the administration of a treatment consisting of dual long-acting HIV-specific broadly neutralizing antibodies (3BNC117-LS & 10-1074-LS (bNAbs)), in combination with an antiretroviral therapy (ART) in individuals with primary HIV-1 infection (PI) when compared to ART only (with neutralizing antibodies or placebo) will favour a period of HIV-1 remission when ART is interrupted 52 or 76 weeks later.

Theme
HIV-1

Population
Adult

Status
Ongoing

If you wish to access biological samples from this study:

Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.

For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr

You are participating or have participated in this study

On the form above, you will find information on the ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.

If you would like to find out more about your participation in a clinical study, please see the section below.

Visit the participant area